CVS Health Corp (CVS) Holding Boosted by First Citizens Bank & Trust Co.

CVS Health Corp (CVS) Holding Boosted by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. increased its stake in shares of CVS Health Corp (NYSE:CVS) by 21.2% during the first quarter, Holdings Channel reports. The institutional investor owned 76,186 shares of the pharmacy operator’s stock after buying an additional 13,351 shares during the period. First Citizens Bank & Trust Co.’s holdings in CVS Health Corp were worth $5,981,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CVS. SRS Capital Advisors Inc. bought a new stake in CVS Health Corp during the fourth quarter valued at approximately $120,000. D Orazio & Associates Inc. boosted its stake in CVS Health Corp by 34.5% in the fourth quarter. D Orazio & Associates Inc. now owns 1,560 shares of the pharmacy operator’s stock valued at $123,000 after buying an additional 400 shares in the last quarter. Elgethun Capital Management bought a new stake in CVS Health Corp during the fourth quarter valued at approximately $133,000. Sowell Financial Services LLC bought a new stake in CVS Health Corp during the fourth quarter valued at approximately $140,000. Finally, Patriot Financial Group Insurance Agency LLC bought a new stake in CVS Health Corp during the fourth quarter valued at approximately $156,000. 81.29% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Corp (NYSE:CVS) opened at 78.29 on Friday. CVS Health Corp has a 1-year low of $69.30 and a 1-year high of $98.67. The firm has a market capitalization of $79.76 billion, a price-to-earnings ratio of 16.33 and a beta of 0.85. The stock’s 50 day moving average is $79.20 and its 200 day moving average is $78.99.

CVS Health Corp (NYSE:CVS) last announced its earnings results on Tuesday, May 2nd. The pharmacy operator reported $1.17 EPS for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.07. CVS Health Corp had a net margin of 3.00% and a return on equity of 17.55%. The firm had revenue of $44.51 billion for the quarter, compared to analysts’ expectations of $44.20 billion. During the same quarter in the previous year, the business posted $1.18 EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Analysts predict that CVS Health Corp will post $5.87 EPS for the current fiscal year.

Several equities research analysts recently commented on CVS shares. Guggenheim reaffirmed a “buy” rating and issued a $90.00 price objective on shares of CVS Health Corp in a research report on Monday, February 6th. Bank of America Corp reaffirmed a “buy” rating and issued a $106.67 price objective on shares of CVS Health Corp in a research report on Tuesday, February 28th. Leerink Swann set a $90.00 price objective on shares of CVS Health Corp and gave the company a “buy” rating in a research report on Saturday, February 11th. Evercore ISI lowered their price target on shares of CVS Health Corp from $91.50 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, February 9th. Finally, Vetr upgraded shares of CVS Health Corp from a “hold” rating to a “buy” rating and set a $85.70 price target on the stock in a research note on Monday, April 3rd. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. CVS Health Corp has an average rating of “Buy” and an average price target of $94.39.

In related news, EVP Troyen A. Brennan sold 23,849 shares of the company’s stock in a transaction dated Tuesday, March 21st. The shares were sold at an average price of $78.73, for a total value of $1,877,631.77. Following the transaction, the executive vice president now owns 94,309 shares in the company, valued at approximately $7,424,947.57. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO David M. Denton sold 95,618 shares of the company’s stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $80.68, for a total transaction of $7,714,460.24. Following the completion of the transaction, the chief financial officer now owns 250,335 shares in the company, valued at approximately $20,197,027.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 139,600 shares of company stock worth $11,205,962. Company insiders own 0.58% of the company’s stock.

CVS Health Corp Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “CVS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Related posts

Leave a Comment